Hermetica Superfood Encyclopedia
The Short Answer
Harpagoside is the primary iridoid glycoside extracted from Harpagophytum procumbens (devil's claw root), responsible for the plant's anti-inflammatory and analgesic properties. It exerts its effects primarily by inhibiting NF-κB signaling and suppressing pro-inflammatory cytokines including IL-6, reducing pain and inflammation at the molecular level.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordharpagoside benefits
Synergy Pairings3
Harpagoside — botanical close-up
Health Benefits
Origin & History
Natural habitat
Harpagoside is a bioactive iridoid glycoside isolated from the secondary roots of Harpagophytum procumbens (devil's claw), a plant native to southern Africa. It is typically extracted using methods that yield high-purity forms (99.9% by HPLC) and serves as the primary marker compound in standardized devil's claw preparations, with commercial extracts containing 2-5% harpagoside.
“Devil's claw roots have been used in southern African traditional medicine for centuries to treat pain, inflammation, and joint issues. Modern European phytotherapy adopted it for similar musculoskeletal complaints, with peer-reviewed studies now supporting these traditional applications.”Traditional Medicine
Scientific Research
A randomized, placebo-controlled, double-blind RCT (PMID: 10101629) tested standardized Harpagophytum extract WS 1531 in 197 patients with acute low back pain, finding dose-dependent benefits at 50-100mg harpagoside daily over 4 weeks. A Cochrane review confirmed pain relief from these doses, though systematic reviews note variable trial quality for osteoarthritis and back pain applications.
Preparation & Dosage
Traditional preparation
Clinically studied doses: 50-100mg harpagoside daily, delivered as standardized root extracts (600-1200mg total extract targeting 2-5% harpagoside content). No specific powder forms were studied in human trials. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Harpagoside is a pure iridoid glycoside compound (C24H30O11, molecular weight 494.49 g/mol), not a whole food ingredient, and therefore contains no macronutrients (protein, fat, carbohydrates), dietary fiber, vitamins, or minerals in its isolated form. As a bioactive phytochemical extracted primarily from Harpagophytum procumbens (Devil's Claw) root, its profile is defined entirely by its bioactive compound characteristics: Harpagoside content in standardized extracts typically ranges from 1–9% w/w in dried Devil's Claw root preparations, with pharmaceutical-grade isolates reaching >98% purity. Clinically studied doses deliver 50–100mg harpagoside daily (corresponding to approximately 1,000–2,400mg of standardized Devil's Claw extract at 4–9% standardization). Bioavailability notes: oral bioavailability is moderate; harpagoside undergoes significant first-pass hepatic metabolism and gut microbiota-mediated hydrolysis, releasing the aglycone harpagogenin, which may represent the primary active metabolite. Peak plasma concentrations are reached approximately 1.3–2.5 hours post-ingestion. Co-administration with food may reduce absorption rate but not total bioavailability. The compound exhibits pH-sensitive stability, with degradation occurring in highly acidic gastric environments, suggesting enteric-coated formulations may improve delivery. No caloric value, glycemic index, or nutrient density metrics are applicable to this isolated compound.
How It Works
Mechanism of Action
Harpagoside suppresses nuclear factor kappa-B (NF-κB) activation, thereby downregulating transcription of pro-inflammatory genes including cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) in chondrocytes and macrophages. It also inhibits 5-lipoxygenase (5-LOX) enzyme activity, reducing leukotriene synthesis and contributing to its dual anti-inflammatory action. Additionally, harpagoside modulates mitogen-activated protein kinase (MAPK) signaling cascades, particularly the ERK and p38 pathways, dampening the overall inflammatory response in synovial and cartilage tissue.
Clinical Evidence
A randomized controlled trial (n=197) demonstrated that 100mg daily harpagoside achieved pain-free status in 10% of low back pain patients versus 3% in the placebo group (P=0.027), representing moderate-quality evidence. Separate RCTs using standardized devil's claw extracts (50–100mg harpagoside daily) have shown statistically significant reductions in WOMAC pain scores for knee and hip osteoarthritis over 8–12 weeks. In vitro studies in human osteoarthritis chondrocytes confirm NF-κB and IL-6 inhibition without cytotoxicity at therapeutic concentrations, supporting the clinical findings mechanistically. Overall evidence is promising but limited by relatively small sample sizes, short trial durations, and variability in extract standardization across studies.
Safety & Interactions
Harpagoside is generally well-tolerated at doses of 50–100mg daily, with the most commonly reported side effects being mild gastrointestinal complaints including diarrhea, nausea, and abdominal discomfort. Due to potential interference with CYP3A4 and CYP2C9 enzyme activity, caution is warranted with co-administration of warfarin, as isolated case reports suggest possible enhancement of anticoagulant effects. Harpagoside may stimulate gastric acid secretion and is contraindicated in individuals with active peptic ulcers or gallstones. Safety data in pregnancy and lactation are insufficient, and its use is not recommended in these populations.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
(1S,4aS,5S,7S,7aS)-5-hydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acid8-p-coumaroylharpagideHarpagide p-coumarateDevil's claw glycosideProcumbideGrapple plant compoundTeufelskralle-Wirkstoff
Frequently Asked Questions
How much harpagoside should I take daily for back pain?
Clinical trials supporting back pain relief have used standardized doses of 50–100mg harpagoside per day, often delivered as a devil's claw root extract standardized to 1–2% harpagoside content. The pivotal RCT (n=197) specifically used 100mg daily and demonstrated significant pain reduction versus placebo (P=0.027). Most trials ran for 8–12 weeks, so short-term use at these doses appears both effective and safe for most adults.
What is the difference between harpagoside and devil's claw extract?
Devil's claw (Harpagophytum procumbens) is the whole root extract, while harpagoside is the specific iridoid glycoside considered its primary active compound, typically constituting 1–3% of dried root by weight. Supplement labels standardized to harpagoside content provide a more reliable and consistent dose compared to unstandardized whole-root powders. Research suggests harpagoside accounts for most, but not necessarily all, of devil's claw's anti-inflammatory activity, as other iridoids like harpagide may contribute.
Does harpagoside interact with blood thinners like warfarin?
Case reports and pharmacological data suggest harpagoside-containing supplements may potentiate the anticoagulant effect of warfarin, potentially by inhibiting CYP2C9-mediated warfarin metabolism or through additive effects on platelet aggregation. Patients taking warfarin or other anticoagulants such as apixaban should consult their physician before using harpagoside and monitor INR levels closely. This interaction is considered possible but not definitively proven in large-scale clinical studies.
How long does it take for harpagoside to work for joint pain?
Most clinical trials report meaningful pain reduction after 4–8 weeks of consistent daily supplementation at 50–100mg harpagoside. Unlike NSAIDs, which act within hours, harpagoside's effects appear to build gradually as NF-κB and COX-2 suppression accumulates over time. Patients in osteoarthritis trials using WOMAC scoring typically showed statistically significant improvements at the 8-week and 12-week assessment points.
Is harpagoside safe for people with stomach ulcers?
Harpagoside stimulates bitter receptors in the gastrointestinal tract, which can increase gastric acid secretion, making it potentially harmful for individuals with active peptic ulcers, gastritis, or duodenal ulcers. This contraindication is well-recognized in European herbal medicine guidelines, and the European Medicines Agency (EMA) monograph for Harpagophytum specifically lists active gastric or duodenal ulcers as a contraindication. People with these conditions should avoid harpagoside supplementation entirely and consult a healthcare provider for alternative anti-inflammatory options.
What does clinical research show about harpagoside's effectiveness for arthritis?
A randomized controlled trial with 197 participants demonstrated that 100mg of harpagoside daily reduced low back pain significantly compared to placebo, with 10% of patients achieving pain-free status versus only 3% in the placebo group (P=0.027). In-vitro studies show harpagoside inhibits IL-6 expression and NF-κB inflammatory pathways in osteoarthritis chondrocytes, though these preliminary findings require clinical confirmation. Overall evidence quality is considered moderate, with more rigorous human trials needed to establish efficacy for other arthritis types beyond low back pain.
Can harpagoside help prevent bone loss or osteoporosis?
Preliminary research suggests harpagoside may support bone health by blocking osteoclastogenesis (bone cell breakdown) through the Syk-PI3K signaling pathway, which could theoretically slow bone loss. However, this mechanism has been identified primarily in laboratory studies and has not yet been validated in human clinical trials for osteoporosis prevention or treatment. Additional research is needed before harpagoside can be recommended as a standalone strategy for bone protection.
Who would benefit most from harpagoside supplementation?
Based on current evidence, harpagoside appears most beneficial for individuals experiencing low back pain, as clinical trials have shown meaningful pain reduction in this population at 100mg daily doses. People with osteoarthritis may also benefit due to harpagoside's anti-inflammatory effects on joint cartilage, though robust clinical evidence specifically for osteoarthritis is still developing. Those seeking natural anti-inflammatory support who have not responded well to other interventions may consider harpagoside, though consultation with a healthcare provider is recommended first.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w harpagoside curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
